Lucas Morgan, Esq

This episode highlights the FDA’s announcement regarding GLP-1 supply stabilization and critical compliance strategies for 503A pharmacies.

Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, present on the significant opportunities and regulatory risks surrounding compounded peptides and GLP-1 products in 2026.

Featuring pharmacist and entrepreneur Sam Maddula, PharmD, this episode explores some key legislative and regulatory insights regarding owning and operating a pharmacy business.

This episode highlights key DSCSA updates in 2026, T3 documentation going forward, and many more developments surrounding the law.

TrumpRx offers discounted cash drug prices like a coupon card but skips PBM reform and raises concerns about deductible gaps and added pressure on independent pharmacies.

This episode highlights the landmark FTC settlement with Express Scripts and what independent pharmacies and plan sponsors can expect going forward.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, provide a timely legal update regarding GLP-1 distribution and compounding.

Independent pharmacies navigate a transformative 2026, benefiting from increased PBM accountability and transparency, fostering a more stable operational landscape.

This episode explores important insights on PBM reform and what pharmacies can look out for throughout 2026.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, explore the evolving world of PBMs within the supply chain as well as the role of state boards of pharmacy.

For pharmacies, TrumpRx could redefine how prescription drugs are distributed and reimbursed.

This episode explores ongoing developments in pharmacy law, specifically for independent pharmacies and their representatives who attended the 2025 NCPA Convention & Expo.

With a new year approaching, pharmacy law experts joined Over the Counter to recap some of the key events regarding state- and federal-level PBM reform throughout 2025.

The final part of our interview with Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, focuses on the relationships between state- and federal-level PBM reform.

At the NCPA 2025 Annual Convention & Expo, Lucas Morgan, Esq, shareholder with Buchanan Ingersoll & Rooney, joined us to discuss ongoing PBM legislation in the state of Arkansas.

Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, shareholders with Buchanan Ingersoll & Rooney, discuss Utah’s pharmacy benefit manager pass-through rebate law.

Before delinking, pharmacy benefit managers were able to tie their fees to significantly high-priced medications, in turn receiving large percentages of compensation rather than flat, fixed fees.

As shortages end, pharmacies that compound GLP-1s face lawsuits, stricter board oversight, and tougher FDA enforcement.

This episode introduces the hosts and explores key legal issues facing independent pharmacies, including PBM terminations and state board compliance.

Dae Lee, PharmD, Esq, CPBS and Lucas Morgan, Esq, discuss PBM and board of pharmacy enforcement actions, trends in PBM audits, and more.